Choosing Between Atezolizumab-Bevacizumab and STRIDE in First-Line Advanced Hepatocellular Carcinoma
International Journal of Science and Research (IJSR) · 24.05.2026 · 1243-1249
DOI: 10.21275/sr26520174441 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Science and Research (IJSR), erschienen am 24.05.2026. Verfasst von Praloy Basu und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Basu, P., Yadav, R., Sunny, G., & Patnaik, A. (2026). Choosing Between Atezolizumab-Bevacizumab and STRIDE in First-Line Advanced Hepatocellular Carcinoma. International Journal of Science and Research (IJSR), 1243-1249. https://doi.org/10.21275/sr26520174441
Vancouver
Basu P, Yadav R, Sunny G, Patnaik A. Choosing Between Atezolizumab-Bevacizumab and STRIDE in First-Line Advanced Hepatocellular Carcinoma. International Journal of Science and Research (IJSR). 2026:1243-1249. doi:10.21275/sr26520174441
BibTeX
@article{Basu2026,
author = {Basu, Praloy and Yadav, Rajan and Sunny, Goutham and Patnaik, Abinash},
title = {Choosing Between Atezolizumab-Bevacizumab and STRIDE in First-Line Advanced Hepatocellular Carcinoma},
journal = {International Journal of Science and Research (IJSR)},
year = {2026},
pages = {1243--1249},
doi = {10.21275/sr26520174441}
}
EUVIMED